BeyondSpring Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BYSI Nasdaq 2830 beyondspringpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BeyondSpring Inc.

Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation - Apr 6th, 2026 4:41 am
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 - Mar 30th, 2026 5:30 am
BeyondSpring Files 2025 Annual Report on Form 10-K - Mar 25th, 2026 2:30 pm
BeyondSpring Reports 2025 Year-End Financial Results - Mar 25th, 2026 6:30 am
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - Feb 9th, 2026 5:15 am
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - Dec 12th, 2025 5:00 am
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 - Dec 11th, 2025 5:00 am
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2025 5:00 am
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation - Oct 28th, 2025 4:06 am
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment - Aug 13th, 2025 6:00 am
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - Jul 7th, 2025 5:00 am
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - Jun 3rd, 2025 5:00 am
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting - May 28th, 2025 5:00 am
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - May 15th, 2025 5:05 am
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - May 12th, 2025 2:30 pm